3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
38
Breast Neoplasms
23
Neoplasms
20
Multiple Myeloma
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Neoplasm Metastasis
13
Recurrence
11
Leukemia, Myeloid, Acute
11
Melanoma
10
Colorectal Neoplasms
10
Carcinoma, Renal Cell
10
Lymphoma, Non-Hodgkin
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Urinary Bladder Neoplasms
8
Lymphoma, Follicular
8
Hematologic Neoplasms
8
Thyroid Neoplasms
7
Stomach Neoplasms
6
Small Cell Lung Carcinoma
6
Sarcoma
6
Prostatic Neoplasms
6
Ovarian Neoplasms
6
Lymphoma, Mantle-Cell
6
Lymphoma, B-Cell, Marginal Zone
6
Lymphoma
6
Lung Neoplasms
6
Head and Neck Neoplasms
6
Colonic Neoplasms
6
Uterine Cervical Neoplasms
5
Thyroid Cancer, Papillary
5
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
1 year
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA